NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis $2.15 -0.07 (-3.15%) Closing price 04:00 PM EasternExtended Trading$2.16 +0.01 (+0.47%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Autolus Therapeutics Stock (NASDAQ:AUTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Autolus Therapeutics alerts:Sign Up Key Stats Today's Range$2.04▼$2.2450-Day Range$1.40▼$2.3352-Week Range$1.17▼$2.43Volume2.39 million shsAverage Volume2.54 million shsMarket Capitalization$572.24 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications. The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma. Additional clinical and preclinical programs address targets such as BCMA in multiple myeloma and solid tumor antigens, as well as novel constructs aimed at improving T cell persistence and tumor microenvironment penetration. Autolus collaborates with academic institutions and research partners to advance its pipeline and validate emerging technologies. Founded in 2014 as a spin-out from University College London, Autolus is headquartered in London, U.K., with operational sites in the United States and Europe to support clinical trials and manufacturing scale-up. The company is led by Chief Executive Officer Christian Itin, whose background in cell therapy and immuno-oncology guides a leadership team of experienced industry executives and scientific experts. Autolus is committed to expanding global access to its therapies through regulatory filings and strategic partnerships in key markets.AI Generated. May Contain Errors. Read More Autolus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreAUTL MarketRank™: Autolus Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 346th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAutolus Therapeutics has a consensus price target of $10.00, representing about 365.1% upside from its current price of $2.15.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Autolus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.97% of the float of Autolus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 16.64, which indicates bearish sentiment.Change versus previous monthShort interest in Autolus Therapeutics has recently decreased by 8.94%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.60 News SentimentAutolus Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Autolus Therapeutics this week, compared to 5 articles on an average week.Search Interest11 people have searched for AUTL on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows2 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUTL Stock News HeadlinesAutolus Therapeutics (NASDAQ:AUTL) Trading Up 13.3% After Earnings BeatAugust 13 at 1:52 AM | americanbankingnews.comAutolus Therapeutics plc (AUTL) Q2 FY2026 earnings call transcriptAugust 12 at 11:58 PM | finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.August 14 at 1:00 AM | Profits Run (Ad)Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Cronos Group (CRON)August 12 at 11:58 PM | theglobeandmail.comAutolus Therapeutics plc 2026 Q2 - Results - Earnings Call PresentationAugust 11 at 3:02 PM | seekingalpha.comAutolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentumAugust 11 at 2:13 PM | msn.comAutolus Therapeutics plc (AUTL) Q2 2026 Earnings Call TranscriptAugust 11 at 1:00 PM | seekingalpha.comAutolus Therapeutics plc: Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 11 at 9:12 AM | finanznachrichten.deSee More Headlines AUTL Stock Analysis - Frequently Asked Questions How have AUTL shares performed this year? Autolus Therapeutics' stock was trading at $1.99 at the start of the year. Since then, AUTL stock has increased by 8.0% and is now trading at $2.15. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) released its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06. The company had revenue of $45.69 million for the quarter, compared to analysts' expectations of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative trailing twelve-month return on equity of 178.66%. Read the conference call transcript. When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $141 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 8,823,530 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' top institutional shareholders include Syncona Portfolio Ltd (6.25%), Alphabet Inc. (0.26%), Hennion & Walsh Asset Management Inc. (0.17%) and GAMMA Investing LLC (0.01%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and Company Calendar Last Earnings8/11/2026Today8/14/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 11 days, AUTL's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AUTL CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees330Year Founded2014Price Target and Rating Average Price Target for Autolus Therapeutics$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+365.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.53 million Net Margins-238.66% Pretax Margin-238.08% Return on Equity-178.66% Return on Assets-49.34% Debt Debt-to-Equity Ratio1.04 Current Ratio4.89 Quick Ratio5.28 Sales & Book Value Annual Sales$117.39 million Price / Sales4.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book7.68Miscellaneous Outstanding Shares266,156,000Free Float197,754,000Market Cap$572.24 million OptionableOptionable Beta2.07 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:AUTL) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredAI insiders stockpile guns, gold & gas masksKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow a rare metal shortage sent gains up 2512 percentIn 2010, a rare earth metal called dysprosium surged 2,512 percent in two and a half years after China cut exp...Awesomely | Sponsored$100 for this… $500 for that. Here’s how to stop the bleeding todayRising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
